Align Technology, Inc. — FY 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. Although the request identifies 2023 Q4, this is an annual filing; the supplied filing text does not provide a clear standalone fourth-quarter income statement or revenue value.
Business context
Align designs, manufactures and sells Invisalign clear aligners and Vivera retainers, iTero intraoral scanners and services, and exocad CAD/CAM software. Clear Aligner accounted for approximately 83% of FY 2023 revenue; Systems and Services accounted for approximately 17%.
Financial and operating results
| Metric | FY 2023 | FY 2022 | Change |
|---|---|---|---|
| Revenue | $3,862.3 million | $3,734.6 million | +3.4% |
| Gross profit / margin | $2,706.9 million / 70.1% | $2,633.8 million / 70.5% | Margin down 0.4 percentage points |
| Operating income / margin | $643.3 million / 16.7% | $642.6 million / 17.2% | Income broadly flat |
| Net income | $445.1 million | $361.6 million | +23.0% |
| Diluted EPS | $5.81 | $4.61 | Up |
| Operating cash flow | $785.8 million | $568.7 million | +$217.0 million |
| Capital expenditures | $177.7 million | $291.9 million | Down |
Clear Aligner revenue rose 4.1% to $3,199.3 million, while case volume increased 0.4% to 2.41 million. Americas case revenue declined 0.6%; international case revenue increased 7.4%. Teenage case volume increased 7.8%. Systems and Services revenue was nearly flat at $662.9 million (+0.1%).
Clear Aligner gross margin declined to 71.5% from 72.5%, with higher manufacturing spend partly offset by higher average selling prices. Systems and Services gross margin improved to 63.2% from 61.3%, supported by service mix and lower purchase price variance. The effective tax rate fell to 30.6% from 39.6%; management attributed the decrease principally to new tax guidance and income mix. This helped net income rise despite nearly unchanged operating income.
Liquidity, debt and capital allocation
Cash, cash equivalents and marketable securities totaled $980.8 million at year-end, down from $1,041.6 million. The company had no borrowings under its $300 million unsecured revolving credit facility, which matures in December 2027, and reported compliance with its requirements. Management said existing cash and available borrowing capacity should fund operations for at least the next 12 months.
FY 2023 financing cash outflow was $598.3 million, primarily reflecting $592.4 million of share repurchases. Approximately $650 million remained available under the January 2023 repurchase authorization at year-end. Purchase commitments totaled $1,234.5 million, of which an estimated $861.5 million was payable within 12 months. Management estimated approximately $100 million of capital expenditures for the next 12 months.
Changes, outlook and notable items
- Revenue growth returned in 2023 after a 5.5% decline in 2022. Management said weaker consumer demand, fewer orthodontic visits and case starts, appointment cancellations, inflation and currency movements weighed on performance, particularly in the second half of 2023.
- Management expects international revenue to grow faster than Americas revenue over the longer term and expects utilization to rise over time, while cautioning that demand and utilization may fluctuate. It anticipated further investment in R&D, manufacturing, treatment planning, sales and marketing in 2024. The filing provides no numerical 2024 revenue or earnings guidance.
- The company continued product launches, including Invisalign Comprehensive 3in3, and received U.S. FDA clearance for the Invisalign Palatal Expander in December 2023. In January 2024 it completed the Cubicure acquisition for approximately $87 million, funded with cash, to develop direct 3D-printing capabilities.
- A fourth-quarter 2023 restructuring plan aimed at organizational efficiencies was expected to be completed in the first half of 2024. FY 2023 restructuring charges were $13.3 million in operating expenses, plus $0.7 million in cost of revenue.
- A useful-life estimate change for certain manufacturing equipment reduced FY 2023 depreciation expense by approximately $5.4 million and increased net income by approximately $3.7 million, or $0.05 per diluted share.
- Geopolitical and operational risks include Middle East conflict affecting Israel-based iTero operations, personnel availability and shipping; the company said the Russia-Ukraine conflict did not materially affect FY 2023 results. Foreign exchange, inflation, competition, cybersecurity and reliance on sole-source suppliers remain significant risks.
Contingencies and controls
HMRC issued an initial VAT assessment of approximately $27 million relating to certain U.K. clear-aligner sales. Align disputes the assessment and did not accrue a loss because it considered a loss not probable; it estimated potential exposure of up to approximately $100 million, excluding interest and penalties, if an unfavorable ruling occurs.
Align reported a $63 million judgment against SmileDirectClub, whose bankruptcy converted to Chapter 7 in January 2024; collection is uncertain. The filing also describes antitrust litigation, including a January 2025 scheduled trial on remaining Section 1 claims in one action. Align said it could not estimate potential losses for these matters. Management and the auditor concluded internal control over financial reporting was effective as of December 31, 2023; the financial statements received an unqualified audit opinion.
Important facts for investors to verify
- Review subsequent quarterly results for whether demand, case starts, utilization and international growth support management’s outlook, and compare margins with FY 2023.
- Track the U.K. VAT dispute, including further assessments, litigation developments, and possible interest or penalties.
- Monitor the antitrust matters and the collectability and timing of the $63 million SDC judgment.
- Assess cash conversion and working capital: FY 2023 operating cash flow benefited from deferred revenue and inventory movements, while accounts receivable was a cash outflow.
- Check the impact of the Cubicure acquisition, restructuring, planned capital spending and remaining share repurchase authorization on liquidity and returns.
- Consider the $3.7 million net-income benefit from the equipment useful-life estimate change and the judgment involved in allocating revenue across treatment-plan obligations.